Q3 2026 Aquestive Therapeutics, Inc. Earnings Conference Call - AQUESTIVE THERAPEUTICS INC

Explicit Guidance:

• Cash Position: Expect to end FY2026 with >$70 million in cash and cash equivalents; as of Q3 2026, standing at $90.3 million (excluding $10M Eton upfront fee).
• Full-Year 2026 Financials: Maintaining guidance for Total Revenue of $46 million to $50 million; Non-GAAP Adjusted EBITDA loss of $30 million to $35 million.
• Future Capital Access: Anticipating access to $75 million under the RTW Strategic Funding Agreement and $20 million under the Oaktree Term Loan Facility upon FDA approval of Anifilm and satisfaction of other conditions.
• LiberVant Licensing Deal: Received $10 million upfront payment; eligible for up to $47.5 million in contingent regulatory/commercial milestones; entitled to mid-teens royalty on annual U.S. net sales.

Business-Segment Outlook:

• Anifilm (Epinephrine Sublingual Film):
  • Regulatory Timeline: FDA PDUFA goal date is 132 calendar days (88 trading days) from Q3 2026; expectation to receive decision by March 16, 2027.
  • Commercial Launch: Targeting a spring 2027 U.S. launch if approved; currently hiring district sales managers and ramping sales force (approx. 75 reps).
  • Target Audience: Focused on ~8,000 high-volume prescribers (allergists, pediatricians, ENTs).
  • International Expansion: Expecting to file Anifilm in Canada by end of 2026; on track to file in Europe in Q1 2027.
  • Market Access: Engaging in pre-approval information exchange (PIE) with top four PBMs and downstream plans to establish coverage quality and percentage of covered lives.
• LiberVant (Diazepam Buccal Film):
  • Commercial Strategy: Out-licensed to Eton Pharmaceuticals; Eton holds exclusive U.S. commercialization rights.
  • Launch Timeline: Expect launch in the U.S. in 2027 if approved; Equestive will remain the exclusive manufacturer/supplier under a long-term agreement.
  • Role: Not central to growth story but expected to be an important cash contributor.
• Manufacturing Base: Suboxone manufacturing revenue up year-to-date; base business remains stable and strong, supporting upcoming Libervant and Anifilm production.

Market and Competitive Outlook:

• Market Trend: Anticipating overall U.S. epinephrine prescription market to grow year-over-year in 2027; expecting a structural transition from auto-injectors to improved technologies like Anifilm.
• Value Proposition: Differentiation based on "speed" (stopping severe reactions quickly) rather than just convenience; focus on pharmacodynamic (PD) data to drive clinician confidence over pharmacokinetic (PK) comparisons.
• Competitive Positioning: Positioning Anifilm as a "360-degree" solution for anaphylaxis management; noting that the auto-injector dominance is historical rather than data-driven.
• Adreniverse Pipeline: 2027 expected to be a pivotal year for the platform; aiming to deliver meaningful clinical data for QST 108 (Atopic Dermatitis) and bring additional epinephrine pro-drug indications to proof of concept.

Macro / Industry Outlook:

• Regulatory Environment: Acknowledging FDA timeline constraints but advocating for a faster review process based on public FDA goals for transparency; maintaining that the review scope is strictly limited to addressing previous Complete Response Letter items.
• Payer Dynamics: Recognizing PBMs' focus on cost management; strategy involves proving clinical differentiation and data to justify premium pricing over generic auto-injectors.
• Operational Execution: Continued focus on disciplined capital allocation to fund launch readiness, regulatory strategy, and selective pipeline investment.

Strategic Initiatives:

• Sales Force Build: Recruiting and training district sales managers to support a targeted launch.
• Payer Engagement: Advancing productive dialogue with PBMs prior to approval to facilitate market access.
• Pipeline Focus: Shifting energy post-resubmission to the Adreniverse platform, specifically Atopic Dermatitis (QST 108) and other epinephrine pro-drug indications beyond dermatology.
• Capital Structure: Refinanced debt in May 2026 to avoid June principal payments; maintaining liquidity to fund launch without immediate dilution (excluding potential RTW/Oaktree tranches).

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: FDA decision timeline is out of company control; possibility of review delays or rejection.
• Commercial Execution: Success dependent on payer contract negotiations, market uptake among physicians, and spending efficiency (cost vs. uptake).
• Market Adoption: Potential hesitation from providers/patients accustomed to auto-injectors; need to prove trust and confidence in the new technology.
• Pipeline Delays: Timing of Atopic Dermatitis clinical data and other platform indications depends on development progress.

Management Tone on the Future:

• Confidence Level: High confidence in execution ("right on schedule"), clinical data (PD focus), and market opportunity ("significant," "compelling").
• Strategic Clarity: Emphasis on "efficiency" and "discipline" regarding cash and launch spending.
• Shift in Messaging: Moved from PK-centric data to PD-centric messaging to better resonate with clinicians and patients; expresses strong belief in the product's ability to "deliver confidence."
• Momentum: Describes gaining momentum with the FDA, cash position, and commercial preparation; views 2027 as a pivotal execution year.

Miscellaneous:

• Key Metrics: Anifilm's peak heart rate/blood pressure response (TE max) ranges from 5–8 minutes, compared to 11+ minutes for comparators in existing studies.
• Pricing Strategy: Pricing details withheld until launch; typical launch tools (copay cards, patient support hubs) will be utilized.
• Non-GAAP Adjustments: Q3 2026 results excluded a one-time $11.7M loss on debt extinguishment; 9-month 2026 net loss adjusted to $35.7M excluding this item.